F5, Inc. (Nasdaq: FFIV) reported third-quarter fiscal 2023 earnings per share (EPS) of $3.21 and revenue of $702.64 million, surpassing the consensus estimate of $2.86 on revenue of $699.39 million for the period.

$FFIV is currently trading at $163.45 in after-hours, reflecting a notable increase of $13.24 (+8.81%).

In other news, NextGen Healthcare, Inc. (Nasdaq: NXGN) announced first-quarter fiscal 2024 adjusted EPS of $0.24 and revenues of $178.21 million, exceeding the consensus estimate of $0.22 on revenue of $173.47 million.

The company has raised its full-year revenue guidance to the range of $714 million to $722 million, up from the prior guidance range of $712 million to $722 million.

$NXGN is trading at $17.45, up $0.92 (+5.57%) in the extended session.

Additionally, Inter Parfums, Inc. (Nasdaq: IPAR) disclosed second-quarter 2023 revenue of $309 million, while analysts were expecting quarterly revenue of $281.81 million.

Driven by a healthy fragrance market and ongoing consumer demand, along with most of the company's brands outperforming and gaining market share, Inter Parfums has raised its 2023 net sales guidance to $1.3 billion, up from $1.25 billion.

In after-hours, $IPAR is trading at $136.10, showing a gain of $5.15 (+3.93%)

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)